The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans

Journal of Pharmaceutical Sciences

Volumn 104, Issue 9, 2015, Pages 3199-3207

  Nguyen, Mai Anh ^a   Staubach, Petra ^b   Wolffram, Siegfried ^c   Langguth, Peter ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

bioavailability; cytochrome P450; drug interactions; flavonoids; gastrointestinal; metabolism; midazolam; pharmacokinetics; quercetin

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 3A; MIDAZOLAM MALEATE; QUERCETIN; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG HALF LIFE; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDAZOLAM; QUERCETIN;

EID: 84939253279     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24500     Document Type: Article

References (35)

1. Egert S, Rimbach G,. 2011. Which sources of flavonoids: Complex diets or dietary supplements? Adv Nutr 2 (1): 8-14.
2. Thomson P, Jones J, Evans JM, Leslie SL,. 2012. Factors influencing the use of complementary and alternative medicine and whether patients inform their primary care physician. Complement Ther Med 20 (1-2): 45-53.
3. Cermak R., 2008. Effect of dietary flavonoids on pathways involved in drug metabolism. Expert Opin Drug Met 4 (1): 17-35.
4. Harwood M, Danielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC,. 2007. A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcino genic properties. Food Chem Toxicol 45 (11): 2179-2205.
5. Boots AW, Haenen GRMM, Bast A,. 2008. Health effects of quercetin: From antioxidant to nutraceutical. Eur J Pharmacol 585 (2-3): 325-337.
6. Cermak R, Wein S, Wolffram S, Langguth P,. 2009. Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci 38 (5): 519-524.
7. Nguyen MA, Staubach P, Wolffram S, Langguth P,. 2014. Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans-Implications for the evaluation of transporter-mediated flavonoid-drug interactions. Eur J Pharm Sci 61: 54-60.
8. Galetin A, Gertz M, Houston JB,. 2010. Contribution of intestinal cytochrome P450-mediated metabolism to drug-drug inhibition and induction interactions. Drug Metab Pharmacokinet 25 (1): 28-47.
9. Thelen K, Dressman JB,. 2009. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61 (5): 541-558.
10. Thummel KE, Wilkinson GR,. 1998. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol 38: 389-430.
11. Sergent T, Dupont I, Van der Heiden E, Scippo ML, Pussemier L, Larondelle Y, Schneider YJ,. 2009. CYP1A1 and CYP3A4 modulation by dietary flavonoids in human intestinal Caco-2 cells. Toxicol Lett 191 (2-3): 216-222.
12. Choi JS, Piao YJ, Kang KW,. 2011. Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 34 (4): 607-613.
13. Umathe SN, Dixit PV, Kumar V, Bansod KU, Wanjari MM,. 2008. Quercetin pretreatment increases the bioavailability of pioglitazone in rats: Involvement of CYP3A inhibition. Biochem Pharmacol 75 (8): 1670-1676.
14. Chung E, Nafziger AN, Kazierad DJ, Bertino JS,. 2006. Comparison of midazolam and simvastatin as cytochromc P450 3A probes. Clin Pharmacol Ther 79 (4): 350-361.
15. Gorski JC, Hall SD, Vandenbranden M, Wrighton SA, Jones DR,. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome-P450-3a (Cyp3a) Subfamily. Biochem Pharmacol 47 (9): 1643-1653.
16. Thummel KE, OShea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR,. 1996. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59 (5): 491-502.
17. Zhang Y, Huo MR, Zhou JP, Xie SF,. 2010. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Meth Prog Bio 99 (3): 306-314.
18. Link B, Haschke M, Grignaschi N, Bodmer M, Aschmann YZ, Wenk M, Krahenbuhl S,. 2008. Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: Usefulness of saliva as matrix for CYP3A phenotyping. Brit J Clin Pharmacol 66 (4): 473-484.
19. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT,. 2006. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 79 (4): 362-370.
20. Duan KM, Wang SY, Ouyang W, Mao YM, Yang LJ,. 2012. Effect of quercetin on CYP3A activity in Chinese healthy participants. J Clin Pharmacol 52 (6): 940-946.
21. Fasinu P, Choonara YE, Khan RA, Du Toit LC, Kumar P, Ndesendo VMK, Pillay V,. 2013. Flavonoids and polymer derivatives as CYP3A4 inhibitors for improved oral drug bioavailability. J Pharm Sci 102 (2): 541-555.
22. Ho PC, Saville DJ, Wanwimolruk S,. 2001. Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4 (3): 217-227.
23. Choi JS, Jo BW, Kim YC,. 2004. Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57 (2): 313-318.
24. Li XG, Choi JS,. 2009. Effects of quercetin on the pharmacokinetics of etoposide after oral or intravenous administration of etoposide in rats. Anticancer Res 29 (4): 1411-1415.
25. Cao XH, Gibbs ST, Fang LY, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong YQ, Amidon GL, Yu LX, Sun DX,. 2006. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23 (8): 1675-1686.
26. Tang CY, Prueksaritanont T,. 2010. Use of in vivo animal models to assess pharmacokinetic drug-drug interactions. Pharm Res 27 (9): 1772-1787.
27. Zuber R, Anzenbacherova E, Anzenbacher P,. 2002. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6 (2): 189-198.
28. Bieger J, Cermak R, Blank R, de Boer VCJ, Hollman PCH, Kamphues J, Wolffram S,. 2008. Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138 (8): 1417-1420.
29. He N, Edeki T,. 2004. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 11 (3): 206-212.
30. Raucy JL., 2003. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 31 (5): 533-539.
31. Patel J, Buddha B, Dey S, Pal D, Mitra AK,. 2004. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: Changes in P-gp and CYP3A4 activity. Am J Ther 11 (4): 262-277.
32. Canaparo R, Finnstrom N, Serpe L, Nordmark A, Muntoni E, Eandi M, Rane A, Zara GP,. 2007. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol 34 (11): 1138-1144.
33. Patki KC, von Moltke LL, Greenblatt DJ,. 2003. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5. Drug Metab Dispos 31 (7): 938-944.
34. Lin YS, Dowling ALS, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, Thummel KE,. 2002. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 62 (1): 162-172.
35. Yu CP, Wu PP, Hou YC, Lin SP, Tsai SY, Chen CT, Chao PDL,. 2011. Quercetin and rutin reduced the bioavailability of cyclosporine from neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agr Food Chem 59 (9): 4644-4648.